Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study
| Autor: | Hélène Beaussier, O Laprévote, François Coudoré, F. Massicot, N Auzeil, E Raymond, Jean-Baptiste Delmotte |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Sensory system Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine medicine Humans Thermosensing Prospective Studies Prospective cohort study Adverse effect Aged Pain Measurement Aged 80 and over business.industry Cumulative dose Peripheral Nervous System Diseases Hypoesthesia Middle Aged medicine.disease Oxaliplatin Peripheral neuropathy Treatment Outcome Oncology Touch Perception 030220 oncology & carcinogenesis Neuropathic pain Physical therapy Neuralgia Female Neurotoxicity Syndromes medicine.symptom business Colorectal Neoplasms 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cancer treatment and research communications. 17 |
| ISSN: | 2468-2942 |
| Popis: | Purpose To better understand how quantitative sensory testing could help the clinician in the management of oxaliplatin-induced peripheral neuropathy in terms of earlier and more reliable detection, we conducted a two-year prospective study. Methods Thermal sensory assessment, tactile sensory assessment, neuropathic pain assessment and adverse events gradation (NCI-CTC) were performed during treatment and 6 months after treatment completion. Results 35 patients were enrolled and followed-up during one year. Cold and Warm Detection Thresholds were higher 6 months after treatment completion than at enrollment. Mechanical detection thresholds didn't change significantly. Neurotoxicity was mostly grade-1, only 18% grade-2 and no grade-3. Grade-2 patients received lower oxaliplatin cumulative dose than grade-1, which reveals effective dose adaptation and grade-2 patients were more likely to develop painful neuropathy. Conclusion Thermal thresholds impairment emerges too late to help the clinician in the prophylaxis of neuropathy. Management of OXA-treatment based on NCI-CTC, as currently recommended, remains the best way to detect neuropathy and ensure treatment adaptation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect